GB0116151A
GB0116151D0
(en)
|
2001-07-02 |
2001-07-02 |
Therapeutic agent
|
CA2452986A
CA2452986C
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent
|
DK02745565.8T
DK1404367T3
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-HIV goat serum as a therapeutic agent
|
IL15968202A
IL159682A0
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent
|
EP02745565A
EP1404367B1
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent
|
EA200400134A
EA013517B1
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent for the preparation of a medicament
|
KR10-2004-7000049A
KR20040030786A
(en)
|
2001-07-02 |
2002-07-02 |
Therapeutic agent
|
MXPA04000147A
MXPA04000147A
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent.
|
PCT/GB2002/003037
WO2003004049A2
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent
|
ES02745565T
ES2351207T3
(en)
|
2001-07-02 |
2002-07-02 |
USE OF ANTI-HIV GOAT POLYCLONAL SERUM AS A THERAPEUTIC AGENT.
|
US10/482,399
US20100291102A1
(en)
|
2001-07-02 |
2002-07-02 |
Therapeutic Agent
|
CNB028171705A
CN100423776C
(en)
|
2001-07-02 |
2002-07-02 |
Therapeutic agent
|
BR0210772-4A
BR0210772A
(en)
|
2001-07-02 |
2002-07-02 |
Uses of an anti-hla antibody, and a goat serum composition
|
HU0401392A
HU228957B1
(en)
|
2001-07-02 |
2002-07-02 |
Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
|
KR1020097007314A
KR100938590B1
(en)
|
2001-07-02 |
2002-07-02 |
Use of Polyclonal Anti-HIV Goat Serum as a Therapeutic Agent
|
AT02745565T
ATE478681T1
(en)
|
2001-07-02 |
2002-07-02 |
USE OF POLYCLONAL ANTI-HIV GOAT SERA AS A THERAPEUTIC AGENT
|
DE60237447T
DE60237447D1
(en)
|
2001-07-02 |
2002-07-02 |
USE OF POLYCLONAL ANTI-HIV GOUGENES AS A THERAPEUTIC AGENT
|
NZ530393A
NZ530393A
(en)
|
2001-07-02 |
2002-07-02 |
High titre antibodies to FAS (CD95/Apo-1) might lead to the inhibition of toxic chemokines, which are thought to be involved in MS induced disability
|
AU2002317285A
AU2002317285B2
(en)
|
2001-07-02 |
2002-07-02 |
Use of polyclonal anti-HIV goat serum as a therapeutic agent
|
JP2003510059A
JP5014562B2
(en)
|
2001-07-02 |
2002-07-02 |
Remedy
|
PL367828A
PL216741B1
(en)
|
2001-07-02 |
2002-07-02 |
Therapeutic agent
|
ZA200400656A
ZA200400656B
(en)
|
2001-07-02 |
2004-01-27 |
Use of polyclonal anti-HIV goat serum as a therapeutic agent.
|
HK04107658.4A
HK1064936A1
(en)
|
2001-07-02 |
2004-10-06 |
Use of polyclonal anti-hiv goat serum as a therapeutic agent
|
JP2009091136A
JP5128539B2
(en)
|
2001-07-02 |
2009-04-03 |
Remedy
|
US13/315,830
US20120100156A1
(en)
|
2001-07-02 |
2011-12-09 |
Therapeutic Agent
|
IL221708A
IL221708A
(en)
|
2001-07-02 |
2012-08-30 |
Goat anti-hla class ii antibody for treatment of cancer
|
US13/763,435
US20130230600A1
(en)
|
2001-07-02 |
2013-02-08 |
Therapeutic agent
|
US14/793,716
US20160002320A1
(en)
|
2001-07-02 |
2015-07-07 |
Therapeutic agent
|